Jane Street Group LLC Sells 1,345,226 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI)

Jane Street Group LLC decreased its stake in Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 86.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 204,750 shares of the company's stock after selling 1,345,226 shares during the quarter. Jane Street Group LLC owned 0.16% of Karyopharm Therapeutics worth $170,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Acadian Asset Management LLC acquired a new position in Karyopharm Therapeutics in the second quarter valued at about $167,000. Point72 DIFC Ltd acquired a new position in shares of Karyopharm Therapeutics in the 2nd quarter valued at approximately $31,000. Cubist Systematic Strategies LLC bought a new stake in Karyopharm Therapeutics during the 2nd quarter worth approximately $494,000. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Karyopharm Therapeutics in the second quarter valued at approximately $143,000. Finally, AQR Capital Management LLC increased its position in shares of Karyopharm Therapeutics by 494.5% during the second quarter. AQR Capital Management LLC now owns 748,020 shares of the company's stock worth $649,000 after acquiring an additional 622,194 shares in the last quarter. Institutional investors own 66.44% of the company's stock.

Karyopharm Therapeutics Trading Down 5.9 %

Shares of KPTI traded down $0.04 during midday trading on Tuesday, reaching $0.63. The stock had a trading volume of 674,240 shares, compared to its average volume of 937,968. The firm has a market cap of $79.90 million, a PE ratio of -0.56 and a beta of 0.07. The firm has a 50 day simple moving average of $0.76 and a 200-day simple moving average of $0.81. Karyopharm Therapeutics Inc. has a one year low of $0.58 and a one year high of $1.95.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.27) by $0.01. The business had revenue of $38.78 million for the quarter, compared to the consensus estimate of $37.86 million. During the same quarter in the previous year, the business posted ($0.30) EPS. As a group, research analysts forecast that Karyopharm Therapeutics Inc. will post -0.94 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on KPTI. StockNews.com downgraded shares of Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research report on Friday, November 22nd. Piper Sandler raised their price objective on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an "overweight" rating in a report on Wednesday, November 6th. Finally, HC Wainwright reiterated a "buy" rating and set a $7.00 target price on shares of Karyopharm Therapeutics in a report on Friday, November 1st. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $5.00.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).